AR and neoplasm: An alternative approach to AR pathway inhibition is to reduce the receptor in tumor cells by its degradation via the ubiquitin-proteasomal pathway, which can be initiated by a small-molecule SARD (Specific AR Degrader) or AR-selective PROTAC (proteolysis-targeting chimera) [58,85].